Stryker Corporation

Is Stryker publicly traded?
Yes. Stryker Corporation trades on the New York Stock Exchange under the ticker SYK and is an S&P 500 component.

When was Stryker founded?
Dr. Homer Stryker founded the Orthopaedic Frame Company in 1941 in Kalamazoo, Michigan. It was renamed Stryker Corporation in 1964 and went public in 1979.

Who owns Stryker?
Stryker is a public company with institutional investors holding most shares. Kevin Lobo has served as CEO since 2012.

What brands does Stryker own?
Stryker's key brands include the Stryker masterbrand, Mako SmartRobotics (surgical robots), Sage Products (patient care), and Vocera (clinical communications). Its 2025 acquisition of Inari Medical added venous thromboembolism devices.

What is Stryker's revenue?
Stryker reported net sales of $25.1 billion for fiscal year 2025, up 11.2%, with net earnings of $3.2 billion and adjusted EPS of $13.63.

Dr. Homer Stryker, an orthopaedic surgeon and inventor, founded the Orthopaedic Frame Company in Kalamazoo, Michigan, in 1941 to manufacture his inventions, including the turning frame for patients and a walking heel cast. The company was renamed Stryker Corporation in 1964 and went public in 1979.

Under CEO John Brown (1977 to 2004), Stryker grew through acquisition into a diversified medical technology company. The 1992 acquisition of osteonics leader Osteo and the 1998 purchase of Howmedica from Pfizer established its orthopaedic implant business. Acquisitions continued with Image Guided Technologies, Physio-Control (1998), and MAKO Surgical (2013, $1.65 billion), which brought the robotic surgery platform that became Stryker's signature technology.

Under CEO Kevin Lobo since 2012, Stryker accelerated its deal cadence: Sage Products (2016, $2.8 billion), Entellus Medical (2018), K2M spine (2018), Wright Medical (2020, $4.7 billion), Vocera Communications (2022, $2.97 billion), and more recently Molli Surgical, Vertos Medical, and Inari Medical (2025, $4.9 billion, its largest acquisition, adding peripheral vascular thrombectomy). In April 2025, Stryker completed the divestiture of its U.S. spinal implants business to VB Spine, sharpening the orthopaedics portfolio.

FY2025 delivered $25.1 billion in net sales, up 11.2%, with organic growth of 10.3%, the strongest recent performance in the company's history. Adjusted EPS rose 11.8% to $13.63.

Stryker publishes an annual comprehensive report covering emissions, product stewardship, and reprocessing programs (its Stryker Sustainability Solutions division collects and reprocesses single-use devices). The company has set carbon reduction targets and reports third-party-verified emissions data. Stryker was named to Fortune's 100 Best Companies to Work For repeatedly.

Stryker has appeared on Fortune's World's Most Admired Companies and Best Companies to Work For lists for more than a decade. Mako SmartRobotics has received medical device innovation recognition, and the company was named MedTech Company of the Year in several industry rankings.

Stryker's most significant legal episode involved metal hip implants: the 2012 recall of its Rejuvenate and ABG II modular neck stems led to a settlement exceeding $1 billion in 2014, with a second settlement announced in 2018. In 2007 the company paid $16.6 million to resolve an SEC Foreign Corrupt Practices Act matter. Product recalls and FDA warning letters occur periodically, as is common for medical device manufacturers.